Loading
Tryptophan and Brain Disorders / Sleep and Related Disorders · Journal article
Microbiology Spectrum · September 9, 2026
Raises a question worth testing. It does not answer one.
This retrospective multi-omics study of 3,026 CRC patients across seven cohorts uses unsupervised clustering to derive two insomnia-related molecular subtypes (IS1/IS2) and develops an insomnia score (ISscore) that correlates with survival, immune infiltration patterns, and microbiome composition. The work is exploratory and hypothesis-generating; it does not establish causality between insomnia and CRC, nor does it provide prospective validation or clinical trial evidence for the proposed ISscore in therapy prediction.
Retrospective multi-cohort multi-omics analysis with unsupervised clustering. Colorectal cancer patients from seven independent cohorts, including a large well-annotated COCC (Clinical Omics study of Colorectal Cancer in China) cohort. Specific eligibility criteria, geographic distribution, stage, treatment status, and demographic details not provided.. Intervention: None; observational multi-omics profiling and unsupervised molecular clustering based on genomic, transcriptomic, and microbiome data.. Compared with: None; unsupervised clustering identified IS1 versus IS2 subtypes; no explicit control arm.. n = 3,026. Multi-cohort analysis; primary cohort (COCC) conducted in China; geographic distribution of other six cohorts not specified..
Unsupervised clustering identified two distinct molecular subtypes (IS1/IS2), with IS2 demonstrating significantly poorer survival IS2 exhibited increased immunosuppression-related infiltration and exhausted T cell signatures versus IS1 IS2 microbiome characterized by depletion of Ruminococcaceae UCG-002 and enrichment of Hungatella/Selenomonas
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should view this as an exploratory framework that may inform future study design and hypothesis testing, not as a validated tool for risk stratification or therapy selection. Prospective studies with direct insomnia measurement and clinical trial validation of the ISscore would be needed before clinical adoption.
This is an exploratory multi-omics association study using unsupervised clustering to identify molecular subtypes linked to insomnia features in CRC; it raises mechanistic questions and generates a risk score but lacks prospective validation, a comparator arm, or hard clinical outcome data to support causal inference or clinical action.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should view this as an exploratory framework that may inform future study design and hypothesis testing, not as a validated tool for risk stratification or therapy selection. Prospective studies with direct insomnia measurement and clinical trial validation of the ISscore would be needed before clinical adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Emerging evidence implicates insomnia as a potential risk factor in carcinogenesis, potentially involving systemic inflammation, circadian disruption, and microbiome alterations. However, the molecular associations linking insomnia-related features to colorectal cancer (CRC), particularly with respect to tumor biology, immune microenvironmental states, and therapy-relevant phenotypes, remain largely unexplored. Multi-omics integration of genomic, transcriptomic, and microbiome data from 3,026 CRC patients across seven independent cohorts, including a large, well-annotated Clinical Omics study of Colorectal Cancer in China (COCC) cohort, enabled insomnia-based molecular classification through unsupervised non-negative matrix factorization (NMF) clustering. The insomnia subtype (IS) was biologically characterized via pathway enrichment, immune deconvolution, microbial profiling, and single-cell transcriptomics. Furthermore, an insomnia score (ISscore) was developed and validated in multiple cohorts for risk stratification and assessment of treatment-response-related indicators in CRC. Unsupervised clustering revealed two distinct molecular subtypes (IS1/IS2), with IS2 demonstrating significantly poorer survival. IS2 exhibited marked activation of EMT/angiogenesis pathways versus cell cycle activation in IS1. The IS2 microenvironment showed increased immunosuppression-related infiltration and exhausted T cell signatures, together with intratumoral microbiome variation characterized by depletion of Ruminococcaceae UCG-002 and enrichment of Hungatella/Selenomonas. The ISscore system stratified survival risk and was associated with computational indicators of immunotherapy response. Single-cell analysis nominated PPIA-BSG as a potential cell-cell communication signal involving high-ISscore tumor cells, CXCL12+ endothelial cells, and CLEC9A+ dendritic cell subsets. This multi-omics characterization of insomnia-CRC interplay suggests that insomnia-related molecular features are associated with an immunologically distinct and microbiome-altered tumor ecosystem. The ISscore provides a reproducible framework for capturing insomnia-related molecular heterogeneity, supporting risk stratification and future evaluation of therapy-relevant phenotypes.IMPORTANCEChronic insomnia affects millions, but it is not typically considered a cancer risk factor. Our study, analyzing vast biological data from over 3,000 colorectal cancer patients, uncovers a potential link between a person's predisposition to insomnia and their risk of developing this disease. This suggests that the biological pathways related to sleep may play a role in cancer development. Understanding this connection opens up new avenues for identifying individuals at higher risk and developing novel prevention strategies for colorectal cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.